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Abstract
Introduction—Approximately 80% of children currently survive 5 years following diagnosis of
their cancer. Studies based on limited data have implicated certain cancer therapies in the
development of ocular sequelae in these survivors.
Procedure—The Childhood Cancer Survivor Study (CCSS) is a retrospective cohort study
investigating health outcomes of 5+ year survivors diagnosed and treated between 1970 and 1986
compared to a sibling cohort. The baseline questionnaire included questions about the first
occurrence of 6 ocular conditions. Relative risks (RR) and 95% confidence intervals (CI) were
calculated from responses of 14,362 survivors and 3,901 siblings.
Results—Five or more years from the diagnosis, survivors were at increased risk of cataracts
(RR:10.8; 95% CI: 6.2–18.9), glaucoma (RR: 2.5; 95% CI: 1.1–5.7), legal blindness (RR: 2.6;
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95% CI: 1.7–4.0), double vision (RR:4.1; 95% CI: 2.7–6.1), and dry eyes (RR: 1.9; 95% CI: 1.6–
2.4), when compared to siblings. Dose of radiation to the eye was significantly associated with
risk of cataracts, legal blindness, double vision, and dry eyes, in a dose-dependent fashion. Risk of
cataracts were also associated with radiation 3000+ cGy to the posterior fossa (RR: 8.4; 95% CI:
5.0–14.3), temporal lobe (RR: 9.4; 95% CI: 5.6–15.6), and exposure to prednisone (RR:2.3; 95%
CI:.1.6–3.4)
Conclusions—Childhood cancer survivors are at risk of developing late occurring ocular
complications, with exposure to glucocorticoids and cranial radiation being important
determinants of increased risk. Long-term follow-up is needed to evaluate potential progression of
ocular deficits and impact on quality of life.
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Introduction
With improvements in multi-modality therapies and supportive care over the past three
decades, almost 80% of all children diagnosed with a malignancy will become long-term
survivors (1–3). At present, it is estimated that there are over 300,000 survivors of childhood
cancer in the United States and by 2010 an estimated 1 of every 570 young adults will be a
childhood cancer survivor (4–6). The combined modality therapies that led to such
improvements in survival also place survivors at risk of developing late effects of treatment
(7). Studies have found that approximately two-thirds of childhood cancer survivors report
at least one chronic medical condition related to their diagnosis and/or therapy (4–5).
Neurosensory complications affecting the auditory, ocular, olfactory, or speech systems are
commonly reported by survivors. A prospective study by Lackner et al. (8) found that 22%
of childhood cancer survivors reported auditory or ocular late effects during the first decade
following treatment. Ocular sequelae observed in childhood cancer survivors include
cataracts, keratoconjunctivitis sicca, and vision loss. Treatment-related factors, specifically
radiation and glucocorticoids, are established risk factors for the development of eye-related
complications (9–10). Although multiple studies have investigated ocular late effects and
treatment associations, many are hampered by small sample sizes, lack of a comparison
group, or vague treatment details.
This study reports the results of an analysis of the long-term ocular-related outcomes in a
large cohort of survivors of childhood cancer diagnosed between 1970–1986. Our primary
aims were 1) to describe the risk of specific ocular complications with respect to survivors’
at 5 years since diagnosis; 2) to compare the occurrence of these ocular complications
among survivors to their occurrence among a sibling control group; and 3) to evaluate the
effect of specific cancer treatments on the risk of developing late ocular complications five
or more years post-diagnosis.
Methods
Patient Selection and Contact
The Childhood Cancer Survivor Study (CCSS) is a multi-institutional collaborative study of
individuals who survived at least 5 years after diagnosis of cancer during childhood or
adolescence and who met the following criteria: 1) diagnosis of leukemia, kidney tumor,
bone tumor, soft tissue sarcoma, neuroblastoma, Hodgkin disease, non-Hodgkin lymphoma,
or primary central nervous system malignancy of any histologic subtype; 2) diagnosis and
Whelan et al. Page 2













treatment at 1 of 26 collaborating institutions; 3) diagnosis date between January 1, 1970
and December 31, 1986; 4) age less than 21 years old at diagnosis (11).
The CCSS research protocol and subject contact documents were approved by the Human
Subjects Committees at each participating institution. At study entry, a 24-page self-
administered baseline questionnaire was sent to eligible study participants. This
questionnaire contained queries pertaining to demographic variables, medical conditions,
surgical procedures, and other health outcomes. A copy of the baseline survey can be found
at: www.stjude.org/ccss.
Of the 20,688 eligible 5-year survivors, 3,123 (15.6%) were lost to follow-up, and therefore
could not be contacted for participation. Of the remaining 17,565 cases, 14,362 (81.8%)
completed the baseline questionnaire and 3,203 (18.2%) declined to participate. Of the
participants, 13,247 (92.2%) gave consent to abstract information from their medical
records. Excluding participants on active cancer treatment at the time of the baseline
questionnaire and those with incomplete medical records resulted in 12,480 survivors for the
current analysis. Nearest age siblings of randomly selected participants were invited to
participate as the control population. Of the 4,855 siblings sent a questionnaire, 3901
(80.4%) completed the baseline questionnaire. Comparison analysis is based on these 3901
siblings.
Data Collection
Ocular deficits considered in this analysis included the following: legally blind in one or
both eyes, cataracts, glaucoma, double vision, retinal conditions, and very dry eyes requiring
drops or ointment. The questions were introduced with the phrase "Have you ever been told
by a doctor or other health care professional that you have, or have had… " Possible
responses were “yes”, “no”, and “not sure”. If the respondent answered “yes”, they were
asked to indicate the age at first occurrence of the condition. Information abstracted from
medical records included their initial therapy, salvage therapy for recurrent disease, and
bone marrow transplant preparative regimens (if applicable). Detailed qualitative
information was obtained on 42 chemotherapeutic agents. For this analysis, glucocorticoid
drugs were defined as receiving either prednisone or dexamethasone. The medical record
abstraction form is available at www.stjude.org/ccss.
Radiation Dosimetry
Within the CCSS, 8,507 patients were documented to have been treated with radiation
therapy. Cut-off dates for exposure to radiation were set at 5 years from the diagnosis date of
the primary cancer. To quantify radiation exposure, right and left eye doses were calculated
for all patients. Doses were based on measurements in a water phantom with corrections
made for eye blocking (12). The eye was assumed to be blocked for patients treated with
whole brain irradiation. In addition, maximum radiation doses were estimated for the
posterior fossa and temporal lobe (which encompasses part of the optic nerve) segment of
the brain (9). A brain segment was considered in the radiation field if at least half of the
segment was included in the primary radiation volume. For those that received radiotherapy
to the brain, radiation exposure to each segment was categorized as either less than 3000
cGy or greater than or equal to 3000 cGy.
Data Analysis
Outcomes were evaluated within two time periods: diagnosis to the 5 year anniversary of the
original diagnosis (Period 1), and 5 or more years post-diagnosis (Period 2). In the event that
a survivor or sibling reported a condition but did not report the age at first occurrence,
multiple-imputation methodology for event time imputation was performed using a slightly
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modified version of the technique of Taylor et al. (13–14) to create ten imputed values for
each missing age. Age, gender, primary diagnosis, and therapy were used to model the rate
of development of each ocular condition, with effects of therapy allowed to change across
the two time periods. Therapies included specific radiation fields and two glucocorticoid
drugs: dexamethasone and prednisone. The imputation method for siblings did not include
diagnosis and therapy information. In analyses run on a data set with complete case data
(ages not imputed), estimates for were within the 95% confidence intervals from the
imputed analyses.
The relative risk (RR) for developing each ocular condition in the time period ≥ 5 years
post-diagnosis, comparing the survivors to the siblings, was estimated by Poisson regression
(15), adjusting for gender, and with a cubic spline function for age. Potential within-family
correlation was accounted for using generalized estimating equations (16).
The prevalence ratio (PR) at study entry was estimated by dividing the observed count of the
condition among survivors by an expected count for the years from diagnosis to 5 years
based on an outcome rate from the age and gender- matched siblings. Statistical inference
was based on bootstrap samples.
Multivariable Poisson probability models, adjusted for age and gender, were used among
survivors to evaluate the impact of eye or brain segment radiation and glucocorticoid drugs
on the risk of developing each ocular condition ≥ 5 years post-diagnosis. Busulfan was
excluded from the final models as too few cases were exposed (n=47). Cumulative incidence
curves, starting with the 5-year anniversary of the primary cancer diagnosis, were
constructed using the method described in Gooley et al. (17).
RESULTS
The slight male predominance in the survivor group was not noted in the sibling comparison
group (53.7% compared with 48.1%, see Table I). Survivors were younger than siblings,
with 77% less than 30 years old at initial contact versus 63% of siblings. More than 60%
were younger than 10 years old at diagnosis. Leukemia was the most common diagnosis,
accounting for about one-third of the survivor cohort.
Reported Occurrence of Ocular Conditions and Relative Risk Compared to Siblings
For all ocular conditions other than glaucoma, the prevalence of the condition among
survivors at 5 years post-diagnosis, relative to siblings, was 2 to 5 fold higher than the rate
ratio reported five or more years post-diagnosis (table II). During the period 5+ years post-
diagnosis, the risk among survivors was significantly higher (p value <0.05) relative to
siblings for all conditions other than retinal condition. We looked at possible correlations
between reports of multiple ocular conditions. Among 438 survivors who reported dry eyes
5+ years post-diagnosis, 29 survivors (7%) also reported double vision and 26 (6%) also
reported cataracts. At 5 or more years post- diagnosis, 815 survivors (5.67%) reported a first
occurrence of an ocular late effect. Two ocular conditions were reported in 96 survivors
(0.67%) and only 19 survivors (0.13%) reported 3 or more ocular complications (data not
shown in table).
Diagnosis and Treatment Related Factors for Specific Conditions Occurring ≥ 5 Years
Post-Diagnosis
Dry eyes requiring drops or ointments were associated with prior treatment with
dexamethasone (RR: 1.8; 95% CI: 1.3–2.6, Table III). Eye radiation doses greater than 500
cGy were associated with a statistically significant increased risk of dry eyes (RR: 6.4; 95%
CI: 3.4–12.0, for greater than 4000 cGy, Table IV) compared to those with no radiation to
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the eye. In addition, radiation doses greater than or equal to 3000 cGy to the temporal lobe
demonstrated an increased risk of dry eyes (RR 1.8; 95% CI: 1.3–2.6, Table V). The median
time from diagnosis to the onset of very dry eyes was 7.2 years with a range of 0.0–26.7
years. In analyzing the effect of diagnosis on the risk of dry eyes, it was found that the
cumulative incidence at 20 years post-diagnosis was greatest for leukemia survivors
(cumulative incidence= 5.1%; 95% CI 4.1–6.1, Table VI) and primary CNS malignancy
survivors (cumulative incidence= 5.3%; 95% CI 3.8–6.8). The cumulative incidence of self-
reported dry eyes, which required treatment, continued to increase up to 25 years after
diagnosis for survivors who received > 500 cGy of radiation to the eye (Fig 1, D).
Survivors who received radiation doses greater than 500 cGy to the eye reported an
increased risk of double vision (RR: 4.3; 95% CI: 2.6–7.1 for 501–1200 cGy). An increased
risk was also seen for radiation doses ≥3000 cGy to the temporal lobe or posterior fossa
(RR: 5.7; 95% CI: 3.7–8.7 and RR: 6.5; 95% CI: 4.2–10.1, respectively). The median time
from diagnosis to the onset of double vision was 2.2 years with a range of 0.0–26.5 years. At
20 years post-diagnosis, those diagnosed with a primary CNS malignancy had the greatest
cumulative incidence of double vision (cumulative incidence= 5.7%; 95% CI 4.1–7.3).
Among those who received > 500 cGy radiation to the eye, the cumulative incidence of
reported double vision continued to increase up to 20 years after diagnosis (Fig 1, C). A
statistically significant decrease in the risk of double vision was present among those
exposed to prednisone (RR: 0.6; 95% CI: 0.4–1.0).
Radiation was associated with an increased risk of legal blindness. Specifically, radiation
doses greater than 500 cGy to the eye (RR: 5.3; 95% CI: 2.8–10.2 for 501–1200 cGy), any
radiation to the posterior fossa, and radiation doses > 3000 cGy to the temporal lobe (RR:
5.7; 95% CI: 3.2–10.1) were associated with a statistically significant increased risk of
reporting being legally blind in 1 or both eyes. The median time from diagnosis to the onset
of legal blindness was 1.0 year with a range of 0.0–23.5 years. Legal blindness at 20 years
post-diagnosis was more common in survivors who were treated for soft tissue sarcomas
(cumulative incidence=1.9%; 95% CI 1.0–2.9) and primary CNS tumors (cumulative
incidence= 1.8%; 95% CI 1.1–2.6). Cumulative incidence of legal blindness continued to
increase up to 20 years post-diagnosis for those treated with radiation to the eye at doses
>500 cGy (Fig 1A). Prednisone was inversely associated with legal blindness (RR: 0.6; 95%
CI: 0.3–0.9). Further analysis of the 107 survivors reporting late onset legal blindness
revealed that the majority were diagnosed with solid tumors (26 primary CNS tumor, 18 soft
tissue sarcoma, 4 Ewing sarcoma, 1 osteosarcoma, 9 neuroblastoma, 10 Hodgkin’s
lymphoma, and 9 kidney tumors) and were not treated with prednisone. Furthermore, out of
the 31 survivors who were treated with prednisone and reported late onset legal blindness,
24 also received brain or total body irradiation.
An increased risk of cataracts was reported in survivors who had been treated with
prednisone (RR: 2.3; 95% CI: 1.6–3.4) and radiation. This increased risk was present at
radiation doses greater than 200 cGy to the eye (RR: 3.2; 95% CI: 2.0–5.2 for 201–500
cGy), and all doses to the posterior fossa and temporal lobe (e.g. RR: 9.4 95% CI: 5.6–15.6
for ≥3000 cGy to the temporal lobe). The median time from diagnosis to the onset of
cataracts was 4.7 years with a range of 0.0–24.1 years. At 20 years post-diagnosis, those
diagnosed with leukemia (cumulative incidence= 3.5%; 95% CI 2.9–4.2) and a primary CNS
malignancy (cumulative incidence= 2.1%; 95% CI 1.3–3.0) had the greatest cumulative
incidence of cataracts. Cumulative incidence of cataracts continued to increase up to 20
years after diagnosis for those who received radiation to the eye (doses >500 cGy) (Fig 1B).
Risk of self-reported retinal conditions was not associated with exposure to prednisone or
dexamethasone (Table III). The only increase in risk due to radiation was present among
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survivors who received radiation doses to the eye of greater than 2000 cGy (RR: 6.3; 95%
CI: 1.8–22.3 for radiation doses greater than 4000 cGy). Analysis of risk of retinal
conditions based on diagnosis revealed low cumulative incidences at 20 years post
diagnosis, with the greatest incidence being seen in survivors of Hodgkin lymphoma
(cumulative incidence= 1.3%; 95% CI 0.7–2.0). Analyses of diagnosis or treatment-related
risks or for glaucoma did not provide any statistically significant associations. The median
time from diagnosis to the onset of retinal conditions was 6.9 years (range 0.0–24.2 years)
and the median time to the onset of glaucoma was 10.3 years (range 0.0–23.8).
DISCUSSION
Previous studies have investigated the prevalence of ocular complications in childhood
cancer survivors, often targeting specific disease populations (18–23). The current study
adds new information by providing risk estimates for the occurrence of eye-related late
effects 5 or more years post-diagnosis, with follow-up spanning up to 25 years. The
availability of detailed treatment information, including radiation dosimetry to the eye and
optic nerve, allowed for investigation of treatment-related risk factors, which can directly
inform guideline-based recommendations for long-term follow-up.
The large size, prolonged follow-up period, and diverse diagnosis and treatment
characteristics of the CCSS cohort provide a unique opportunity to characterize and quantify
the risk of ocular late effects. With the large number of survivors in the cohort it was
necessary to rely upon self-reported ocular outcomes. While well-defined ocular outcomes
were selected for inclusion in the questionnaire, and self-reported data from survivors were
compared to self-reported data from the sibling cohort, it is important to acknowledge that
the potential exists for misclassification (I.e., either under- or over-reporting) of outcomes.
The lens is the most sensitive structure of the eye to the effects of ionizing radiation (21).
Early studies in adults found that a single dose of 200 cGy or multiple, fractionated doses of
radiation at a minimum total dose of 400 cGy could lead to cataract formation (10,21). We
found that even low doses of radiation to the eye resulted in an increased risk of cataract
formation, which increased with increasing dose. Previous reports have found that latency
period and severity of cataracts after total body irradiation is also influenced by other
factors, such as steroid treatment for graft versus host disease (GVHD) (18–20). The
mechanism triggering the formation of posterior subcapsular cataracts due to chronic high
doses glucocorticoid use is controversial (24–25). One opinion is the oxidation of lens
proteins and changes to lens hydration by steroids will induce cataract formation. Other
theories include glucocorticoid receptor activation leading to changes in transcription of
specific genes, such as RGC32 protein, which has been reported to induce cellular
proliferation (24–25). While our study found that prednisone was associated with cataract
formation, we found no increased risk of cataracts in survivors treated with dexamethasone,
possibly due to the small number of survivors in the CCSS cohort exposed to
dexamethasone.
A known complication of radiation to the orbit is severe dry eyes, also known as
keratoconjunctivitis sicca, with symptoms increasing when the dose to the eye is > 4000 cGy
(26–28). Radiation may damage the lacrimal apparatus through various mechanisms,
including scarring of the canaliculi and puncta and failure of the lacrimal pump due to
decreased eyelid mobility (10). This complication was observed in our survivors with as
little as 500 cGy radiation to the eye. Other factors within CCSS survivors could also
account the increased risk of severe dry eyes. For example, 6.8% of CCSS survivors who
reported late onset dry eyes had received total body irradiation, presumably as part of a
preparative regimen for a bone marrow transplant. This subset would be at risk for the
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development of chronic GVHD, which frequently affects the eye and manifests as
keratoconjunctivitis sicca (22). Specific information on type of transplant was not collected
for the original CCSS cohort, but will be available for the CCSS cohort expansion that is
currently underway and may provide more insight into the risk of ocular complications after
transplant.
Our analysis identified two associations that require further investigation. The first is the
reported late onset of diplopia. Double vision may be secondary to ocular and brain
conditions, including cataracts, retinal detachment, cranial nerve palsies, astigmatism, or
uncorrected refractory errors (29). We found a modest correlation between diplopia and
other reported ocular conditions, with 6% of survivors with cataracts also reporting double
vision. Second, is the risk of reported late-onset legal blindness. A small percentage of
survivors with late onset blindness also reported cataracts, which may have contributed to
vision loss in 22 out of 107 survivors. In addition, 20 survivors who reported a recurrence of
their primary CNS malignancy or developed a second malignant neoplasm located in the
CNS reported vision loss occurring 5 or more years after initial diagnosis. The underlying
etiology of the reported blindness however, is not clear.
Glucocorticoids appear to have a protective effect against development of some ocular
conditions, such as legal blindness or diplopia. Other studies have noted the beneficial anti-
inflammatory effects of steroids with respect to some eye-related conditions such as keratitis
and macular degeneration (30–31). This finding may be reflective of the underlying cancer
diagnosis, and should be pursued in future research endeavors.
We found no increase in risk of glaucoma among survivors treated with glucocorticoid
therapy. Some reports suggest an increased risk of open angle glaucoma after steroid use due
to alterations in the trabecular meshwork, resulting in impaired aqueous outflow (32). Other
studies have found that increased intraocular pressure after prolonged oral glucocorticoid
therapy is rare (22). It is possible we may have underestimated the true incidence of
glaucoma in survivors, as it is often an asymptomatic condition, difficult to diagnose unless
routine eye exams include measuring intraocular pressure. Additional follow-up may
uncover increased risk of glaucoma in childhood cancer survivors treated with steroid
therapy
In summary, survivors of childhood cancer are at increased risk for ocular late effects,
related to both glucocorticoid and radiationx exposure. This analysis demonstrates that self-
reported eye-related complications continue to manifest more than 5 years after diagnosis.
While some of these effects have a minor impact on survivors’ quality of life, others, such as
blindness and cataracts, may have significant consequences. Continued medical follow-up of
survivors is essential for early detection to minimize the effects of ocular complications, and
to optimizing survivors’ quality of life.
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Cumulative incidence (%) of select ocular conditions and radiation exposure >500 cGy to
eye: >500 cGy to eye, some to brain segments; Brain segment: <=500 cGy to eye, some to
brain segments; No radiation: Zero cGy to eye and brain
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Table III
Glucocorticoid Exposure and Relative Risk of Late Ocular Conditions ≥5 Years Post-Diagnosis
Chemotherapy
Relative Risk* (95% CI)
Ocular Condition Prednisone Dexamethasone
Dry Eyes 1.1 (0.9–1.5) 1.8 (1.3–2.6)b
Double Vision 0.6 (0.4–1.0) a 1.4 (0.8–2.6)
Legally Blind 0.6 (0.3–0.9) a 1.0 (0.4–2.5)
Cataracts 2.3 (1.6–3.4) b 1.2 (0.8–1.9)
Retinal Condition 0.7 (0.4–1.2) 1.6 (0.6–4.1)
Glaucoma 0.6 (0.2–1.6) ---
*
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Table V
Radiation Dose to Various Regions of the Brain and Risk of Late Ocular Conditions ≥5 Years Post-Diagnosis
Relative Risk* (95% CI)
Posterior Fossa Temporal Lobe
Ocular Condition <3000 cGy ≥3000 cGy <3000 cGy ≥3000cGY
Dry Eyes 1.0 (0.8–1.3) 1.4 (1.0–2.1) 1.0 (0.7–1.2) 1.8 (1.3–2.6) b
Double Vision 1.3 (0.9–1.9) 6.5 (4.2–10.1) b 1.2 (0.8–1.8) 5.7 (3.7–8.7) b
Legally Blind 1.8 (1.1–3.1)a 3.6 (1.9–7.0) b 1.4 (0.8–2.4) 5.7 (3.2–10.1) b
Cataracts 2.9 (1.9–4.7) b 8.4 (5.0–14.3) b 2.7 (1.7–4.3) b 9.4 (5.6–15.6) b
Retinal Condition 1.5 (0.8–2.6) 2.1 (0.9–4.9) 1.5 (0.8–2.6) 2.0 (0.9–4.5)
Glaucoma 1.7 (0.6–4.3) 3.0 (0.8–10.8) 1.6 (0.6–4.2) 3.0 (0.8–10.6)
*
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